Isabelle Kenyon, Calibrate founder and CEO

Type 2 di­a­betes drugs and weight loss: Cal­i­brate's mod­el starts with phar­ma and builds out

Cal­i­brate is look­ing to up­end the weight loss in­dus­try. And thanks to the drug in­dus­try, it’s got a se­cret weapon – GLP-1 meds.

Over the past few years, next-gen­er­a­tion Type 2 di­a­betes treat­ments have of­ten chat­ted up the weight-loss side ben­e­fit in TV com­mer­cials. Ac­tors and pa­tients in ads have of­ten said things like, “And I may even lose a lit­tle weight,” across cam­paigns for the glucagon-like pep­tide-1 brands such as Eli Lil­ly’s Trulic­i­ty and No­vo Nordisk’s Vic­toza, Ozem­pic and Ry­bel­sus.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.